Search for: "Morgan v. Doe et al"
Results 41 - 60
of 194
Sorted by Relevance
|
Sort by Date
2 May 2015, 10:24 am
AL., Appellants, v. [read post]
8 Feb 2017, 3:09 am
Ltd. et al. v. [read post]
13 Oct 2016, 6:50 am
Ltd. et al. v. [read post]
24 Apr 2017, 4:43 am
Montgomery et al., 2016-0790. [read post]
6 May 2011, 7:03 am
District Court in the Central District of California of the class action in Genevive La Court, et al. v. [read post]
4 Mar 2016, 12:25 pm
Morgan, et al. v. [read post]
24 Jun 2022, 9:05 pm
Morgan v Kerik, 267 AD2d 8, 9 [1st Dept 1995]; Simpson v Abate, 213 AD2d 190, 191 [1st Dept 1994]). [read post]
24 Jun 2022, 9:05 pm
Morgan v Kerik, 267 AD2d 8, 9 [1st Dept 1995]; Simpson v Abate, 213 AD2d 190, 191 [1st Dept 1994]). [read post]
10 Feb 2008, 11:27 am
FuturaGene, plc, et al., (Del. [read post]
29 Nov 2022, 4:13 am
AL., 26A FEDERAL PRACTICE & PROCEDURE: EVIDENCE § 5679 (1st ed.) [read post]
3 Jun 2016, 6:40 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
18 Apr 2016, 9:58 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
28 Dec 2011, 10:52 am
Brody, et al., 11-civ-4164 (S.D.N.Y.; Dec. 16, 2011).) [read post]
5 Mar 2019, 5:15 am
In Mercedes-Benz USA, LLC, et al v. [read post]
16 Jan 2017, 5:44 pm
Ltd. et al. v. [read post]
26 Jul 2013, 12:04 pm
Morgan Securities Inc., et al. v. [read post]
3 May 2016, 1:42 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
26 Mar 2010, 4:28 pm
At about 11 a.m. on Monday, the Supreme Court will hear one hour of oral argument in Morrison, et al., v. [read post]
1 Apr 2016, 8:22 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
18 May 2016, 8:19 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]